JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information

Takeshi Sagara, Executive Director, Clinical Development and Medical Affairs, Discovery & Preclinical Research at Taiho, stated: “We believe that future anticancer drug discovery focusing on research and development, not only for advanced cancer, but also for early-stage recurrent cancer, with an eye on the patient journey, will lead to long-term survival and ultimately the overcoming of cancer. We are very pleased to begin this new initiative together with JFCR and NEC toward creating novel cancer vaccines. Utilizing our proprietary patented evaluation models, we will play a key role in evaluating target cancer antigens and identifying clinical trial candidates continuing our challenge in tackling intractable cancers.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib